Thor Medical ASA (TRMED) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Thor Medical ASA (TRMED) has a cash flow conversion efficiency ratio of -0.104x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-47.54 Million ≈ $-5.00 Million USD) by net assets (Nkr456.00 Million ≈ $47.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Thor Medical ASA worth for the company's overall valuation and market capitalisation.
Thor Medical ASA - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Thor Medical ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Thor Medical ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Thor Medical ASA ranked by their cash flow conversion efficiency. See how well can Thor Medical ASA service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GTM Holdings Corp
TW:1437
|
-0.002x |
|
Winton Land Ltd
AU:WTN
|
-0.019x |
|
Centratama Telekomunikasi Ind
JK:CENT
|
-0.011x |
|
High Tide Inc
NASDAQ:HITI
|
0.057x |
|
Critical Holdings Berhad
KLSE:0291
|
-0.070x |
|
Anhui Provincial Architectural Design and Research Institute Co.Ltd.
SHE:301167
|
N/A |
|
Naturgy BAN SA
BA:GBAN
|
0.231x |
|
Coca Cola HBC AG
LSE:CCH
|
0.137x |
Annual Cash Flow Conversion Efficiency for Thor Medical ASA (2020–2025)
The table below shows the annual cash flow conversion efficiency of Thor Medical ASA from 2020 to 2025. View today's stock price for Thor Medical ASA for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Nkr456.00 Million ≈ $47.98 Million |
Nkr-47.54 Million ≈ $-5.00 Million |
-0.104x | -48.29% |
| 2024-12-31 | Nkr337.10 Million ≈ $35.47 Million |
Nkr-23.70 Million ≈ $-2.49 Million |
-0.070x | +70.17% |
| 2023-12-31 | Nkr271.93 Million ≈ $28.61 Million |
Nkr-64.09 Million ≈ $-6.74 Million |
-0.236x | +96.32% |
| 2022-12-31 | Nkr63.84 Million ≈ $6.72 Million |
Nkr-409.08 Million ≈ $-43.05 Million |
-6.408x | -123.17% |
| 2021-12-31 | Nkr140.52 Million ≈ $14.79 Million |
Nkr-403.46 Million ≈ $-42.46 Million |
-2.871x | -28.83% |
| 2020-12-31 | Nkr178.67 Million ≈ $18.80 Million |
Nkr-398.21 Million ≈ $-41.90 Million |
-2.229x | -- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.